Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities-Reference-Cited by-同舟云学术

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities

Published:2017-06-29 Issue:40 Volume:8 Page:67782-67789
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Costa Ricardo¹,Costa Rubens B.¹,Talamantes Sarah M.²,Helenoswki Irene³,Carneiro Benedito A.¹,Chae Young Kwang¹,Gradishar William J.¹,Kurzrock Razelle⁴,Giles Francis J.¹

Affiliation:

1. Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

2. Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

3. Northwestern University Department of Preventive Medicine, Chicago, Illinois, USA

4. Center for Personalized Cancer Therapy, Moores Cancer Center, University of California at San Diego, La Jolla, California, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of photodynamic therapy on immune system in cancer – an update;Frontiers in Immunology;2024-02-28

2. Recent advances in light-triggered cancer immunotherapy;Journal of Materials Chemistry B;2024

3. Nanotechnology Potent Photothermal and Photodynamic Immunotherapies of Cancer;Journal of Medical and Biological Engineering;2023-11-10

4. Management of trophoblastic tumors : review of evidence, current practice, and future directions;Expert Review of Anticancer Therapy;2023-05-22

5. Adverse drug reactions associated with immune checkpoint inhibitors: An exploratory nested case-control study in a historical cohort;Therapies;2022-07